Cargando…
Random survival forests identify pathways with polymorphisms predictive of survival in KRAS mutant and KRAS wild-type metastatic colorectal cancer patients
KRAS status serves as a predictive biomarker of response to treatment in metastatic colorectal cancer (mCRC). We hypothesize that complex interactions between multiple pathways contribute to prognostic differences between KRAS wild-type and KRAS mutant patients with mCRC, and aim to identify polymor...
Autores principales: | Naseem, Madiha, Cao, Shu, Yang, Dongyun, Millstein, Joshua, Puccini, Alberto, Loupakis, Fotios, Stintzing, Sebastian, Cremolini, Chiara, Tokunaga, Ryuma, Battaglin, Francesca, Soni, Shivani, Berger, Martin D., Barzi, Afsaneh, Zhang, Wu, Falcone, Alfredo, Heinemann, Volker, Lenz, Heinz-Josef |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8190302/ https://www.ncbi.nlm.nih.gov/pubmed/34108518 http://dx.doi.org/10.1038/s41598-021-91330-z |
Ejemplares similares
-
KRAS and BRAF genotyping of synchronous colorectal carcinomas
por: GIANNINI, RICCARDO, et al.
Publicado: (2014) -
Impact of genetic variants involved in the lipid metabolism pathway on progression free survival in patients receiving bevacizumab-based chemotherapy in metastatic colorectal cancer: a retrospective analysis of FIRE-3 and MAVERICC trials
por: Wang, Jingyuan, et al.
Publicado: (2023) -
Pharmacogenomics in colorectal cancer: current role in clinical practice and future perspectives
por: Battaglin, Francesca, et al.
Publicado: (2018) -
Reply: KRAS status analysis and anti-EGFR therapies: is comprehensiveness a biologist's fancy or a clinical necessity?
por: Cremolini, C, et al.
Publicado: (2010) -
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
por: Volz, Nico B., et al.
Publicado: (2020)